Appendix 4C

31 January 2019

Melbourne, Australia and Leatherhead, UK

CLINUVEL PHARMACEUTICALS LTD, a global biopharmaceutical company focused on developing and delivering treatments for patients with a range of severe genetic and skin disorders, today announced its Appendix 4C – Quarterly Cashflow report for the period 01 October to 31 December 2018. All figures are rounded and reported in Australian dollars.

Download PDF to read more

We use cookies to give you the best experience.